Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Filgrastim in Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* People with probable AD (by NINDS/ADRDA criteria) who are likely to be testable at the conclusion of the study period, and who do not have concurrent medical conditions or medications that might influence cognitive testing or that would increase the risk of treatment~* The participants will have a Min Mental State Examination score of between 10 and 24~* stable medical condition and stable medications for 3 months prior to screening~* study partner (spouse or caregiver) to accompany patient to all scheduled visits; able to complete baseline assessments~* physically acceptable for this study as confirmed by medical history, physical exam, neurological exam and clinical tests~Exclusion Criteria:~* clinically significant cardiac arrhythmia~* history of clinically significant stroke~* use of another investigational drug within 2 months of screening~* current evidence or history in the past 2 years of epilepsy, focal brain lesion, head injury with loss of consciousness or DSM-IV criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder alcohol or substance abuse; residence in a skilled nursing facility (but patients in assisted living facility are acceptable)

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- G-CSF (filgrastim) first phase (Type: EXPERIMENTAL): Subjects assigned to this arm receive G-CSF for 5 days during the first phase of the study. At week 7 these subjects cross over to receive placebo injections for five days
- Placebo first phase (Type: PLACEBO_COMPARATOR): Subjects assigned to this arm receive placebo injections daily for 5 days; after wk 7 they crossover to receive 5 daily injections of injections of G-CSF.

Based on this trial design, predict the completion outcome and termination type (if applicable).